Paradise Valley businessman applies a lifetime of "systems
management" expertise to help speed research practices
Phoenix, AZ, April 4, 2005--The Translational Genomics Research
Institute (TGen) today announced that Paradise Valley businessman
and entrepreneur, Mr. Ray Thurston, has pledged $3 million to
support three breast cancer research projects.
Mr. Thurston is not only providing funding; he is bringing his
years of supply chain management and logistics experience to help
accelerate TGen's research programs. He is interested in
streamlining processes that expedite research and ultimately reduce
the time required for the development of new diagnostic tests and
drug treatments.
"So many medical problems touch all of our lives," said Mr.
Thurston. "I was attracted to the focus that TGen has on
compressing the time it takes to move discoveries from the
laboratory into new diagnostics and treatments. I hope that the
process of shrinking the timeline within a business framework might
be of value to future TGen research projects."
Mr. Thurston has extensive expertise in delivering proven results.
With over four decades of experience, Mr. Thurston is considered
one of the leading authorities on supply chain management. He began
his career as a bicycle courier for his father's delivery business
and went on to found his own same-day air courier company,
Scottsdale-based SonicAir, in 1976. Under Thurston's leadership,
SonicAir evolved into a full-service supply chain logistics company
that gave customers access to the fastest available delivery.
United Parcel Service (UPS) acquired SonicAir in 1995 and in 1996
named Thurston CEO of the UPS Logistics Group. He retired in 1998
after doubling their revenue.
Paradise Valley businessman Mr. Ray Thurston (left) discusses lab
results with TGen Investigator Dr. Heather Cunliffe. In addition to
his $3 million donation to TGen, Mr. Thurston is bringing his years
of supply chain management and logistics experience to help
accelerate TGen's research programs. He is interested in
streamlining processes that expedite research and ultimately reduce
the time required for the development of new diagnostic tests and
drug treatments.
What also makes Mr. Thurston unique is his willingness to roll up
his sleeves and work in the lab alongside TGen researchers. Dr.
Heather Cunliffe, head of TGen's Breast Cancer Research Unit, has
been training Mr. Thurston in molecular biology, including
mandatory lessons in laboratory safety. He also takes an active
role in monthly lab meetings, where TGen researchers discuss
scientific progress and review budgets and timelines. By
understanding the research Mr. Thurston will be better equipped to
identify process improvement possibilities.
"To the students and staff in the lab, Ray is a routine trainee,"
said Dr. Cunliffe. "A bit older (and wiser perhaps) than most new
students, but he has been trained like any other new student,
gaining the necessary scientific understanding to move these
projects forward."
As Mr. Thurston becomes more familiar with the laboratory 'supply
chain', he is meeting with TGen faculty and staff to help outline a
more-business oriented plan in this decidedly scientific
framework.
"The new frontier in bringing the human genome project to patient
application is the integration of complex information from genomic,
medical, and computer studies-a field we call 'systems biology',"
said Dr. Jeffrey Trent, TGen's President and Scientific Director.
"Mr. Thurston has been successfully applying systems management to
the business sector for many years and we are learning ways to
apply these engineering principals to the task of fighting disease.
It is a remarkably unique and productive partnership."
Over the course of this research, Mr. Thurston will stay connected
with progress through the lab and will play an integral role in
helping improve productivity thus shaving time from various
research components.
"It's been such an eye-opening experience to work with Mr.
Thurston," said Dr. Cunliffe. "We have put in place a new
milestone-based model to track projects and budgets to assure that
our outcomes are achieved as quickly as possible."
The breast cancer projects include:
1. A study that will help physicians more accurately
diagnose and treat patients who have a genetic predisposition for
developing breast cancer.
2. A study that will determine which tumors are most
likely to respond to a particular therapy, optimizing treatment for
some women with an appropriate anti-cancer agent and saving others
from expensive unnecessary treatment.
3. A prospective study that will leverage the results
of the previous two studies to determine the most effective
treatments for individual tumors based on their genetic
information.
Using cutting-edge technology, this research will likely identify
molecules that will be targets for novel diagnostics and
therapeutics in breast cancer, a goal in line with TGen's vision of
personalized disease management.
"Since the day it was conceived, TGen hoped to increase the speed
in which genetic discovered were moved into the clinic," said Dr.
Trent. "Applying systems engineering to medical research is where
the future of medicine is heading and we are delighted that Mr.
Thurston is helping us achieve that future even faster."
# # #
About TGen
The Translational Genomics Research Institute (TGen) is a
not-for-profit organization whose primary mission is to make and
translate genomic discoveries into advances in human health.
Translational genomics research is a relatively new field employing
innovative advances arising from the human Genome Project to apply
to the development of diagnostics, prognostics and therapies for
cancer, neurological disorders, diabetes and other complex
diseases.